All Insights

Roughly 97.5% of drug candidates die before a patent is ever filed on them — invisible to competitors, regulators, and the public. This piece breaks down how AI is starting to mine that hidden graveyard, and why no single unpatented failure has turned into a headline win yet.

Pharma companies are promising AI vendors won't misuse their data. This piece breaks down exactly what protects that data — private model copies, encryption, confidential computing — and where those protections still come down to a person getting it right.

Warren Buffett says he could still compound money at 50% a year. The data says the market that let him do that in the 1950s doesn't exist anymore — and here's the specific evidence why.

The medtech ETF beat the pharma ETF over the last decade — not because medtech won, but because two stocks inside it did. Here's what you're actually buying, and why the S&P 500 beat both anyway.

The FDA has cleared 1,451 AI medical devices since 1995. Only two have ever proven they actually change what happens to a patient — everything else has proven it's accurate, not that it matters.

AI is changing medical technology in two opposite ways. Using Abbott's cardiovascular devices and Intuitive Surgical's robotic platform as case studies, this article shows how AI strengthens the core switching-cost moat while gradually eroding the vendor-specific software layer surrounding it.